Publication date: Apr 15, 2019
Anal mucosal melanoma is an uncommon malignancy of the anal canal, with few large studies available to establish clear trends in the treatment modalities presently available. The primary goal of this study was to identify the patterns of care in the treatment of anal melanoma and secondarily to determine outcomes.
This was a retrospective study performed utilizing the National Cancer Database (NCDB). A total of 787 patients diagnosed with anal melanoma between 2004 and 2014 were selected, of which 398 had staging information. The four treatment groups analyzed were surgical excision alone, surgical excision and radiation therapy, surgical excision and immunotherapy/chemotherapy, and radiation therapy plus minus immunotherapy/chemotherapy. Treatment was grouped by extent of disease; the Kaplan-Meier method was used to analyze overall survival and multivariate Cox proportional model was used to identify factors associated with overall survival.
The majority of patients presented with either node-positive (39.4%) or metastatic disease (37.4%). Patients with surgical excision and radiation therapy had the highest median survival at 32.3 months. This is in contrast with those receiving surgical excision alone (22.9 months), surgery and immunotherapy/chemotherapy (18.4 months), and radiation without surgery (5.1 months) (p
Naqvi, J., Lee, A., Lederman, A., Kavi, A., Osborn, V.W., and Schreiber, D. Patterns of Care and Survival Outcomes in the Treatment of Anal Melanoma. 22317. 2019 J Gastrointest Cancer.
- Do Not Forget About the Importance of Loco-Regional Therapy in Melanoma Management.
- Is melanocyte density our last hope? Comparison of histologic features of photodamaged skin and melanoma in situ after staged surgical excision with concurrent scouting biopsies.
- Surgical Management of Localized Melanoma: A National Cancer Database Retrospective Review.
- How Immunotherapy Is Improving Treatment for Melanoma
- Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy.
- [Vemurafenib-induced radiation recall dermatitis].
- SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
- Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
- CheckMate 204:’Practice-Changing’ for Metastatic Melanoma CheckMate 204:’Practice-Changing’ for Metastatic Melanoma